Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02039401 · ClinicalTrials.gov registry record · Phase 1
Safety Study of VM202 to Treat Amyotrophic Lateral Sclerosis
A Phase 1 study, sponsored by Helixmith Co..
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT02039401 is a Phase 1 study that has completed, run by Helixmith Co.. The registered enrollment target is 18 participants.
The verdict
NCT02039401, a Phase 1 study, has completed, sponsored by Helixmith Co..
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety and tolerability of intramuscular injections of VM202 at different injection sites in people with amyotrophic lateral sclerosis.
Interventions
- BIOLOGICAL VM202
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2014-03-11 |
| Est. Completion | 2024-03-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02039401
The ClinicalTrials.gov registry entry for NCT02039401 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Helixmith Co., which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which VM202 is the first listed.
NCT02039401 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02039401 about?
NCT02039401 is a clinical study titled "Safety Study of VM202 to Treat Amyotrophic Lateral Sclerosis". The purpose of this study is to determine the safety and tolerability of intramuscular injections of VM202 at different injection sites in people with amyotrophic lateral sclerosis.
What is the current status of trial NCT02039401?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2014-03-11. Estimated completion is 2024-03-06.
What interventions are being tested in trial NCT02039401?
The interventions under investigation include: VM202 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02039401?
This trial is sponsored by Helixmith Co., which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.